Hypothesis: In COPD, a pound of cure may be better than an ounce of prevention

Stephen I. Rennard; Jorgen Vestbo

doi:10.1136/thx.2010.151498

Hypothesis: In COPD, a pound of cure may be better than an ounce of prevention

Stephen I. Rennard, Jorgen Vestbo

Pulmonary, Critical Care, & Sleep Medicine

Research output: Contribution to journal › Editorial › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	643-645
Number of pages	3
Journal	Thorax
Volume	66
Issue number	8
DOIs	https://doi.org/10.1136/thx.2010.151498
State	Published - Aug 2011

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1136/thx.2010.151498

Cite this

@article{2b0508af2d974517a04e38be5d295851,

title = "Hypothesis: In COPD, a pound of cure may be better than an ounce of prevention",

author = "Rennard, {Stephen I.} and Jorgen Vestbo",

note = "Funding Information: Competing interests Stephen Rennard has served as a consultant or participated in advisory boards for: ABIM, Able Associates, Adelphi Research, Almirall, APT, Aradigm, Argenta, AstraZeneca, Bl (ACCP), Biostrategies, BoomCom, Britnall and Nicolini, Capital Research, Chiesi, Clinical Advisors, CommonHealth, Complete Medical Group, Consult Complete, COPDForum, DataMonitor, Decision Resources, Defined Health, Dey, Dunn Group, Easton Associates, Enterprise Analysis, Equinox, Forest, Fulcrum, Gerson Lehman, GSK, Guidepoint, Hoffman LaRoche, IMS, Informed, Inspire, Insyght, KOL Connection, Leerink Swan, M. Pankove, MDRx Financial, MedaCorp, Medimmune, Mpex, Novartis, Nycomed, Oriel, Otsuka, Pearl, Pennside Partners, Pfizer, Pharma Ventures, Pharmaxis, Pick Research, Prescott, PwC, Propagate, Pulmatrix, Pulmonary Reviews, Quadrant, Reckner Associates, Recruiting Resource, Reviews and Trends in COPD/Convergent Health Solutions, Roche, Sacoor, Schering, Schlesinger Medical, Scimed, Smith Research, Sudler and Hennessey, Talecris, Theravance, UBC, Uptake Medical, Vantage Point. He has received lecture fees from: AAAAI, Am Col Osteopathic Physicians, Asan Medical Center, ATS, AstraZeneca, California Soc Allergy, Convergent Health Solutions for Reviews and Trends in COPD, COPD Foundation, Creative Educational Concepts, Dey, Duke, France Foundation, Information TV, University of California-Los Angeles, Network for Continuing Education, Novartis, Nycomed, Otsuka, Pfizer, Sarasota Mem Hospital, Spanish Thoracic Society, University of Washington, University of Alabama-Birmingham, University of Pittsburgh, University of British Columbia, University of California-Davis, VA Sioux Falls. He has received industry-sponsored grants from: AstraZeneca, Biomarck, Centocor, GlaxoSmithKline, Mpex, Nabi, Novartis, Otsuka, Pfizer. Jorgen Vestbo has received fees for consulting and presenting on issues on COPD treatment from the following pharmaceutical companies: GSK, AstraZeneca, Pfizer, Boehringer-lngelheim, Novartis, Talecris, Chiesi, Hofmann-La Roche and Nycomed – none of which provide a cure for COPD, unfortunately. ",

year = "2011",

month = aug,

doi = "10.1136/thx.2010.151498",

language = "English (US)",

volume = "66",

pages = "643--645",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "8",

}

TY - JOUR

T1 - Hypothesis

T2 - In COPD, a pound of cure may be better than an ounce of prevention

AU - Rennard, Stephen I.

AU - Vestbo, Jorgen

N1 - Funding Information: Competing interests Stephen Rennard has served as a consultant or participated in advisory boards for: ABIM, Able Associates, Adelphi Research, Almirall, APT, Aradigm, Argenta, AstraZeneca, Bl (ACCP), Biostrategies, BoomCom, Britnall and Nicolini, Capital Research, Chiesi, Clinical Advisors, CommonHealth, Complete Medical Group, Consult Complete, COPDForum, DataMonitor, Decision Resources, Defined Health, Dey, Dunn Group, Easton Associates, Enterprise Analysis, Equinox, Forest, Fulcrum, Gerson Lehman, GSK, Guidepoint, Hoffman LaRoche, IMS, Informed, Inspire, Insyght, KOL Connection, Leerink Swan, M. Pankove, MDRx Financial, MedaCorp, Medimmune, Mpex, Novartis, Nycomed, Oriel, Otsuka, Pearl, Pennside Partners, Pfizer, Pharma Ventures, Pharmaxis, Pick Research, Prescott, PwC, Propagate, Pulmatrix, Pulmonary Reviews, Quadrant, Reckner Associates, Recruiting Resource, Reviews and Trends in COPD/Convergent Health Solutions, Roche, Sacoor, Schering, Schlesinger Medical, Scimed, Smith Research, Sudler and Hennessey, Talecris, Theravance, UBC, Uptake Medical, Vantage Point. He has received lecture fees from: AAAAI, Am Col Osteopathic Physicians, Asan Medical Center, ATS, AstraZeneca, California Soc Allergy, Convergent Health Solutions for Reviews and Trends in COPD, COPD Foundation, Creative Educational Concepts, Dey, Duke, France Foundation, Information TV, University of California-Los Angeles, Network for Continuing Education, Novartis, Nycomed, Otsuka, Pfizer, Sarasota Mem Hospital, Spanish Thoracic Society, University of Washington, University of Alabama-Birmingham, University of Pittsburgh, University of British Columbia, University of California-Davis, VA Sioux Falls. He has received industry-sponsored grants from: AstraZeneca, Biomarck, Centocor, GlaxoSmithKline, Mpex, Nabi, Novartis, Otsuka, Pfizer. Jorgen Vestbo has received fees for consulting and presenting on issues on COPD treatment from the following pharmaceutical companies: GSK, AstraZeneca, Pfizer, Boehringer-lngelheim, Novartis, Talecris, Chiesi, Hofmann-La Roche and Nycomed – none of which provide a cure for COPD, unfortunately.

PY - 2011/8

Y1 - 2011/8

UR - http://www.scopus.com/inward/record.url?scp=79960568621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960568621&partnerID=8YFLogxK

U2 - 10.1136/thx.2010.151498

DO - 10.1136/thx.2010.151498

M3 - Editorial

C2 - 21386104

AN - SCOPUS:79960568621

SN - 0040-6376

VL - 66

SP - 643

EP - 645

JO - Thorax

JF - Thorax

IS - 8

ER -

Hypothesis: In COPD, a pound of cure may be better than an ounce of prevention

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this